youtube
In this episode of FYI, Chief Futurist, Brett Winton, and Analyst Nemo Marjanovic speak with Alex Zhavoronkov, founder and CEO of Insilico Medicine. Together, they explore the promise of artificial intelligence in transforming the drug discovery process—cutting years off timelines and dramatically reducing costs. Alex shares Insilico’s journey from algorithm-first beginnings to a full-stack AI-driven biotech company, highlighting their unique “pan flute” model approach to drug development and the vision of building a “pharmaceutical superintelligence.” The discussion touches on Insilico’s clinical progress, including a molecule that recently completed a Phase 2 trial, and how its generative platforms are helping to tackle complex diseases with a focus on longevity.
Key Points From This Episode:
00:00:00 AI's promise in streamlining the drug discovery process
00:03:06 The economics of preclinical development and AI’s role in optimization
00:04:43 Potential cost and timeline reductions: $2.4B down to $600M, 13 years to 8
00:07:39) Comparing Insilico’s approach to peers like Recursion and AbSci
00:10:35 Literature-driven vs. biology-driven models in drug discovery
00:13:07 Why a dominant AI platform could reshape biotech industry consolidation
00:14:57 Why biologics may be more suited to AI than small molecules
00:17:35 Alex Zhavoronkov on founding Insilico and his mission in longevity science
00:21:00 From algorithms to real drugs: Insilico’s transition to clinical developmen
|
2025/07/10
youtube
